Clinical Trial Update: Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Everolimus (RAD001) in metastatic transitional cell carcinoma of the urothelium (bladder cancer) completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Urothelium

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Bladder Cancer, Metastatic Transitional Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-11-25